At the journal club held on Dec 10, 2018 (Azar 19, 97), the interesting topic entitled" Machine learning and its novel role in phramacology and drug discovery" was discussed. A summary of this journal club meeting is in below:
The applications of artificial intelligence (AI) in healthcare are numerous, with the potential to transform key aspects of the industry, such as drug discovery. For many pharmaceutical companies, machine learning is the most important aspect of AI, with the potential to allow machines to ultimately surpass the intelligence levels of humans.
Increasing investments in AI in drug discovery by big pharma suggest a truth behind the benefits of applying machine learning to identify and screen potential drug candidates.
The success of AI in drug discovery is largely due to deep learning, a field of machine learning that is built using artificial neural networks that model the way neurons in the human brain talk to each other. This technology can train systems to analyze large sets of chemical and biological data to identify drug candidates with high success rates much faster than humans.